KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Vertex Pharmaceuticals (VRTX) Leases: 2009-2025

Historic Leases for Vertex Pharmaceuticals (VRTX) over the last 6 years, with Sep 2025 value amounting to $1.6 billion.

  • Vertex Pharmaceuticals' Leases rose 14.02% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 14.02%. This contributed to the annual value of $1.4 billion for FY2024, which is 362.13% up from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Leases of $1.6 billion as of Q3 2025, which was up 21.16% from $1.3 billion recorded in Q2 2025.
  • Vertex Pharmaceuticals' Leases' 5-year high stood at $1.6 billion during Q3 2025, with a 5-year trough of $293.6 million in Q4 2023.
  • Its 3-year average for Leases is $831.3 million, with a median of $569.8 million in 2024.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Leases declined by 15.49% in 2023, and later soared by 362.13% in 2024.
  • Vertex Pharmaceuticals' Leases (Quarterly) stood at $400.1 million in 2021, then fell by 13.17% to $347.4 million in 2022, then fell by 15.49% to $293.6 million in 2023, then surged by 362.13% to $1.4 billion in 2024, then increased by 14.02% to $1.6 billion in 2025.
  • Its Leases was $1.6 billion in Q3 2025, compared to $1.3 billion in Q2 2025 and $1.3 billion in Q1 2025.